...
首页> 外文期刊>BMC Psychiatry >TPH1 A218C polymorphism and temperament in major depression
【24h】

TPH1 A218C polymorphism and temperament in major depression

机译:TPH1 A218C多态性与重度抑郁症的气质

获取原文
           

摘要

Background In major depression, one of the candidate genes possibly affecting the risk and severity of symptoms has been found to be tryptophan hydroxylase (TPH1). Variation in treatment response to antidepressive agents according to TPH1 genotype has also been found in several studies. However, the relationship between temperament and TPH1 genotype in major depression is poorly understood, as only one study has been published so far. There are no earlier studies on the interaction between temperament traits, antidepressive medication response and TPH1 genotype. This interaction was studied in 97 subjects with major depression treated for six weeks with selective serotonine reuptake inhibitors. Methods Temperament dimensions Harm Avoidance (HA), Novelty Seeking (NS), Reward Dependence (RD) and Persistence (P) scores at baseline (1) and endpoint (2) were rated with the Temperament and Character Inventory (TCI) and compared between TPH1 A218C genotypes. Multivariate analysis of co-variance (MANCOVA) was used to analyze the interaction between the TPH1 genotype, treatment response and the different temperament dimensions at baseline and endpoint. In the analysis model, treatment response was used as a covariate and TPH1 genotype as a factor. A post hoc analysis for an interaction between remission status and TPH1 A218C genotype at endpoint HA level was also performed. Results The number of TPH1 A-alleles was associated with increasing levels in NS1 and NS2 scores and decreasing levels in HA1 and HA2 scores between TPH1 A218C genotypes. In the MANCOVA model, TPH1 genotype and treatment response had an interactive effect on both HA1 and HA2 scores, and to a lesser degree on NS2 scores. Additionally, an interaction between remission status and TPH1 A218C genotype was found to be associated with endpoint HA score, with a more marked effect of the interaction between CC genotype and remission status compared to A-allele carriers. Conclusions Our results suggest that in acute depression TPH1 A218C polymorphism and specifically the CC genotype together with the information on remission or treatment response differentiates between different temperament profiles and their changes.
机译:背景技术在严重抑郁症中,已发现可能影响症状风险和严重程度的候选基因之一是色氨酸羟化酶(TPH1)。在TPH1基因型中,对抗抑郁药的治疗反应也有所不同。然而,由于迄今为止仅发表了一项研究,人们对重度抑郁症的气质与TPH1基因型之间的关系了解甚少。气质性状,抗抑郁药物反应和TPH1基因型之间的相互作用尚无早期研究。在97名患有严重抑郁症的受试者中使用选择性5-羟色胺再摄取抑制剂治疗了六周,研究了这种相互作用。方法用气质和性格量表(TCI)对在基线(1)和终点(2)处的气质维度避害(HA),寻求新奇(NS),奖励依赖(RD)和持久性(P)得分进行评分,并进行比较TPH1 A218C基因型。协方差的多变量分析(MANCOVA)用于分析TPH1基因型,治疗反应以及基线和终点时不同气质维度之间的相互作用。在分析模型中,将治疗反应用作协变量,将TPH1基因型用作因素。还对终点HA水平的缓解状态和TPH1 A218C基因型之间的相互作用进行事后分析。结果TPH1 A218C基因型之间的TPH1 A等位基因数目与NS1和NS2评分水平升高以及HA1和HA2评分水平降低相关。在MANCOVA模型中,TPH1基因型和治疗反应对HA1和HA2评分均具有交互作用,对NS2评分的影响较小。另外,发现缓解状态与TPH1 A218C基因型之间的相互作用与终点HA评分相关,与A等位基因携带者相比,CC基因型与缓解状态之间的相互作用具有更明显的影响。结论我们的结果表明,在急性抑郁症中,TPH1 A218C多态性,特别是CC基因型以及缓解或治疗反应的信息,可以区分不同的气质特征及其变化​​。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号